Abstract
We compared concurrent chemoradiotherapy (CCRT) with docetaxel, cisplatin (CDDP), and 5-fluorouracil (5-FU) (TPF) with CCRT with CDDP, 5-FU, methotrexate and leucovorin (PFML) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) in terms of safety and efficacy on survival. A total of 100 patients were enrolled. The TPF group received CCRT with the TPF regimen [docetaxel (50 mg/m2: day 1), CDDP (60 mg/m2: day 4), and continuous 5-FU infusion (600 mg/m2/day: days 1–5)]. In the PFML group, patients received CCRT with the PFML regimen [CDDP (60 mg/m2: day 4)], continuous 5-FU infusion (600 mg/m2/day: days 1–5), methotrexate (30 mg/m2: day 1) and leucovorin (20 mg/m2/day: days 1–5)]. Both groups received 2 cycles of chemotherapy during definitive radiotherapy. The total radiation dose was between 66.6 and 70.2 Gray. The overall response rates after CCRT were 98 with 90% of a pathologically complete response (pCR) in the TPF group and 94 with 77% in the PFML group. For grade 3/4 adverse events, mucositis was more frequent in the PMFL group, and the TPF group showed a higher incidence of hematological toxicity. CCRT with TPF or PMFL for advanced SCCHN was tolerable and produced excellent survival rates.
Similar content being viewed by others
References
Landis SH, Murray T, Bolden S, Wingo PA (1999) Cancer statistics, 1999. CA Cancer J Clin 49:8–31
Clayman GL, Lipman SM, Laramore GE, Ki Hong W (2000) Head and neck neoplasms. In: Holland JF, Kufe DW, Pollock RE et al (eds) Holland–Frei cancer medicine, 5th edn. BC Decker, Philadelphia, pp 1173–1220
Pignon JP, Bourhis J, Domenge C, Designé L, MACH-NC Collaborative Group (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Meta-analysis of chemotherapy on head and neck cancer. Lancet 355:949–955
Monnerat C, Faivre S, Temam S, Bourhis J, Raymond E (2002) End points for new agents in induction chemotherapy for locally advanced head and neck cancers. Ann Oncol 13:995–1006
Bourhis J, Le Maître A, Baujat B, Audry H, Pignon JP, Meta-Analysis of Chemotherapy in Head, Neck Cancer Collaborative Group, Meta-Analysis of Radiotherapy in Carcinoma of Head, Neck Collaborative Group, Meta-Analysis of Chemotherapy in Nasopharynx Carcinoma Collaborative Group (2007) Individual patients’ data meta-analyses in head and neck cancer. Curr Opin Oncol 19:188–194
Pignon JP, Syz N, Posner M, Olivares R, Le Lann L, Yver A, Dunant A, Lewin F, Dalley DN, Paccagnella A, Taylor SG, Domenge C, Bourhis J, Mazumdar M (2004) Adjusting for patient selection suggests the addition of docetaxel to 5-fluorouracil-cisplatin induction chemotherapy may offer survical benefit in squamous cell cancer of the head and neck. Anticancer Drugs 15(4):331–340
Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, van den Weyngaert D, Awada A, Cupissol D, Kienzer HR, Rey A, Desaunois I, Bernier J, Lefebvre JL, EORTC 24971/TAX 323 Study Group (2007) Cisplatin, fluorouracil, and decetaxel in unresectable head and neck cancer. N Engl J Med 357(17):1695–1704
Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, Murphy BA, Raez LE, Cohen RB, Spaulding M, Tishler RB, Roth B, Viroglio Rdel C, Venkatesan V, Romanov I, Agarwala S, Harter KW, Dugan M, Cmelak A, Markoe AM, Read PW, Steinbrenner L, Colevas AD, Norris CM Jr, Haddad RI, TAX 324 Study Group (2007) Cisplatin and fluorouracil alone or with decetaxel in head and neck cancer. N Engl J Med 357(17):1705–1715
Seiwert TY, Cohen EEW (2005) State of the art management of locally advanced head and neck cancer. Br J Cancer 92:1341–1348
Salama JK, Seiwert TY, Vokes EE (2007) Chemoradiotherapy for locally advanced head and neck cancer. J Clin Oncol 25(26):4118–4126
Tsukuda M, Mikami Y, Tanigaki Y, Katori H, Horiuchi C, Ikeda Y, Taguchi T, Ono M, Yoshida T, Sakuma Y, Aikoh K (2004) Phase 1 trial of combined chemotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) for patients with locally locally advanced squamous cell carcinoma of the head and neck. Int J Clin Oncol 9:161–166
Katori H, Tsukuda M, Mochimatu I, Ishitoya J, Kawai S, Mikami Y, Matsuda H, Tanigaki Y, Horiuchi C, Ikeda Y, Taguchi T, Ono M, Yoshida T, Hirose S, Sakuma Y, Yamamoto K (2004) Phase 1 trial of concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Br J Cancer 90:348–352
Katori H, Tsukuda M, Watai K (2007) Comparison of hyperfractionation and conventional fractionation radiotherapy with concurrent docetaxel, cisplatin and 5-fluorouracil (TPF) chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Cancer Chemother Pharmacol 60(3):399–406
Katori H, Tsukuda M (2005) Comparison of induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (TPF) followed by radiation vs concurrent chemoradiotherapy with TPF in patients with locally advanced squamous cell carcinoma of the head and neck. Clin Oncol (R Coll Radiol) 17(3):148–152
Taguchi T, Tsukuda M, Katori H (2006) Concurrent chemoradiotherapy with cisplatin, 5-fluorouracil, methotrexate, and leucovorin in patients with advanced resectable squamous cell carcinoma of the larynx and hypopharynx. Acta Otolaryngol 126:408–413
Katori H, Tsukuda M, Taguchi T (2007) Analysis of efficacy and toxicity of chemotherapy with cisplatin, 5-fluorouracil, methotrexate and leucovorin (PFML) and radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol 59(6):789–794
Taguchi T, Tsukuda M, Mikami Y, Matsuda H, Tanigaki Y, Horiuchi C, Nishimura G, Nagao JI (2009) Treatment results and prognostic factors for advanced squamous cell carcinoma of the head and neck treated with concurrent chemoradiotherapy. Auris Nasus Larynx 36(2):199–204
World Health Organization (1979) WHO Handbook for reporting results of cancer treatment. WHO offset publication No. 48. World Health Organization, Geneva
Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, Peters G, Lee DJ, Leaf A, Ensley J, Cooper J (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349(22):2091–2098
Cohen EE, Lingen MW, Vokes EE (2004) The expanding role of systemic therapy in head and neck cancer. J Clin Oncol 22:1743–1752
Urba SG, Moon J, Giri PG, Adelstein DJ, Hanna E, Yoo GH, Leblanc M, Ensley JF, Schuller DE (2005) Organ preservation for advanced respectable cancer of the base of tongue and hypopharynx: a southwest oncology group trial. J Clin Oncol 23(1):88–95
Adelstein DJ, Saxton JP, Rybicki LA, Esclamado RM, Wood BG, Strome M, Lavertu P, Lorenz RR, Carroll MA (2006) Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer. J Clin Oncol 24(7):1064–1071
Bensadoun RJ, Bénézery K, Dassonville O, Magné N, Poissonnet G, Ramaïoli A, Lemanski C, Bourdin S, Tortochaux J, Peyrade F, Marcy PY, Chamorey E, Vallicioni J, Seng H, Alzieu C, Géry B, Chauvel P, Schneider M, Santini J, Demard F, Calais G (2006) French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 yaers (FNCLCC-GHORTEC). Int J Radiat Oncol Biol Physi 64(4):983–994
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tsukuda, M., Ishitoya, J., Matsuda, H. et al. Randomized controlled phase II comparison study of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil versus CCRT with cisplatin, 5-fluorouracil, methotrexate and leucovorin in patients with locally advanced squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol 66, 729–736 (2010). https://doi.org/10.1007/s00280-009-1217-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-009-1217-0